

Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure

Catherine N. Marti, MD, MSc; Gregg C. Fonarow, MD; Mihai Gheorghiade, MD; Javed Butler, MD, MPH

There are more than a million hospitalizations for heart failure (HHF) annually in the United States¹ and >80% of them occur in patients with known chronic heart failure (HF).^{2,3} These patients have a combined mortality and readmission rate of 35% to 40% within 90 days, a readmission rate of 25% within 30 days, and a mortality rate of 30% within a year after discharge.¹ Many trials have been conducted on these patients and yet there are no approved therapies for these patients with proven efficacy for reducing mortality or readmission.⁴⁻¹² There are many reasons for this,¹³ including the lack of consensus on therapeutic targets and aims. Most trials have focused on short-term dyspnea, but the rapid response to conventional therapy may indicate that dyspnea relief is a largely a met need. These trials have generally intervened by infusing investigational drugs for 2 to 3 days early in the hospital course signifying a philosophy that HHF represents an acute disease with distinct pathophysiology, like acute myocardial infarction, where short-term interventions can improve outcomes¹³ (Figure 1). Myocardial infarction, however, represents a truly acute onset of a distinct pathophysiology (ie, plaque rupture and thrombus formation). Whether HHF is an acute disease representing a distinct pathophysiology is uncertain. The selection of timing and duration of novel intervention among patients with HHF is rooted on fundamental concepts on the acuity of the disease process, its pathophysiology, the timing of adverse events, and past experience.

Subacute Symptom Onset

Some episodes of HHF are truly acute; however, many of these are related to secondary conditions (eg, acute coronary syndrome, rapid atrial fibrillation, or infections). The majority of HHF reflects subacute, progressively worsening congestion.^{1,13} Changes occur 12.4±1.4 days before admission for edema, 11.3±1.6 days for weight gain, and 8.4±0.9 days for dyspnea.¹⁴ Changes in weight frequently begin at least a week before admission.^{15,16} Defibrillators and cardiac resynchronization devices can assess thoracic impedance that may correlate with fluid status and predict worsening HF before symptom onset. Ninety percent of the detected alerts for changes in impedance were followed by

a hospital evaluation for HF within 30 days in 1 study.¹⁷ In another, 53 alert and HF deteriorations were identified in 43 subjects; 83% showed evidence of fluid accumulation several days before the event.¹⁸ In 1 study with ambulatory hemodynamic monitoring, elevated pulmonary artery diastolic pressure correlating with HF events began rising on average 29±22 days before the event¹⁹ (Figure 2). Data with implanted sensors demonstrate that left atrial pressures are most commonly elevated during the 30 days before HF events.²⁰ Many patients do not have acute symptoms when admitted but present on the basis of availability of caregiver, lack of ad hoc outpatient appointment, reaching a threshold of slowly worsening symptoms, or other social issues; some are hospitalized for worsening HF detected during routine clinic visits.

No Distinct Pathophysiology

The abnormalities that have been described in patients with HHF, although exacerbated, mirror those seen in chronic stable patients with HF (Table). If indeed a ruptured plaque HHF pathophysiology is identified, it will forestall a new era of intervention development; however, no such insights have been gained to date. Patients with HHF have a cardiac structure and function that is similar to chronic HF with varying left^{21,22} and right ventricular function,²³ left atrial enlargement, mitral regurgitation, and other abnormalities.²⁴ Both HHF and stable patients show a wide range of hemodynamics ranging from altered filling pressures, afterload, and cardiac output; however, these tend to be worse during hospitalization.²⁵ Neurohormonal activation (plasma renin activity, norepinephrine, vasopressin, copeptin, and adrenomedullin)²⁶⁻²⁹; myocyte damage (troponin)^{30,31}; inflammation (tumor necrosis factor,³² C-reactive protein,³³ interleukin-6,³⁴ and ST-2)³⁵; oxidative stress (isoprostane, aminothiols, uric acid, and myeloperoxidases)³⁶⁻³⁹; extracellular matrix (matrix metalloproteinases and their inhibitor, galactin-3)^{40,41}; myocardial stress (natriuretic peptides)^{42,43}; and renal function (blood urea nitrogen, creatinine, Cystatin C, neutrophil gelatinase-associated lipocalin, and kidney injury molecule)⁴⁴⁻⁴⁸ alterations have all been shown in both patients with HHF and chronic stable HF.

Received April 15, 2013; accepted July 2, 2013.

From the Division of Cardiology, Emory University, Atlanta, GA (C.N.M., J.B.); Division of Cardiology, University of California, Los Angeles (G.C.F.); and Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (M.G.).

Correspondence to Javed Butler, MD, MPH, Division of Cardiology, Emory Clinical Cardiovascular Research Institute, 1462 Clifton Rd, NE, Suite 504, Atlanta, GA 30322. E-mail javed.butler@emory.edu

(*Circ Heart Fail*. 2013;6:1095-1101.)

© 2013 American Heart Association, Inc.

Circ Heart Fail is available at <http://circheartfailure.ahajournals.org>

DOI: 10.1161/CIRCHEARTFAILURE.113.000518




Figure 1. Clinical trials in patients hospitalized for heart failure. Most trials initiated and terminated novel therapies during the acute stages of management. ACTIV indicates Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure; ASCEND, Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; ASTRONAUT, Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure; CASINO, Calcium Sensitizer or Inotrope or None in Low-Output Heart Failure; ECLIPSE, Effect of Tolvaptan on Hemodynamic Parameters in Subjects with Heart failure; EVEREST, Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure; LIDO, Efficacy and Safety of Intravenous Levosimendan Compared with Dobutamine in Severe Low-Output Heart Failure; PROTECT, Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function; RELAX-AHF, Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure; REVIVE, Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short-Term Treatment of Decompensated Heart Failure; RITZ, Randomized Intravenous Tezosentan; RUSSLAN, Randomized Study on Safety and Effectiveness of Levosimendan in Patients with Left Ventricular Failure after an Acute Myocardial Infarct; SURVIVE, Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support; VERITAS, Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies; and VMAC, Vasodilation in the Management of Acute Congestive Heart Failure.

Postdischarge Risk

Current data suggest that patients with HHF have lower in-hospital but higher postdischarge risk for adverse events compared with patients with acute myocardial infarction. The patients with HHF are at a substantially higher risk for death and readmissions compared with stable outpatients with a recent HHF being one of the strongest and most consistent predictors of poor outcomes. Each successive readmission is associated with incrementally higher risk of mortality. The risk for death or readmission is highest within 30 days, and the observed risk decreases significantly within 3 to 6 months. In the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) trial, odds for mortality after discharge following HHF declined from 6-fold in the first month after discharge to 2-fold over time (Figure 3).⁴⁹ Similar data from registries showed a period of increased risk within the first 6 months after discharge.^{50,51} Whether HHF identifies patients at higher risk (a marker) or there are discrete pathophysiologic processes in patients with HHF that contribute the adverse outcomes (a mediator) has not been fully elucidated.

Impact of Short-Term Interventions

The current standard of HHF care, that is, intravenous diuretics, nitrates, and other vasodilators, and in select cases, inotropes are all short-term interventions to improve symptoms

and signs, but none has been shown to improve outcomes after discharge. Most HHF clinical trials have also focused on short-term intravenous infusions and none has improved postdischarge outcomes, barring 1 trial. Seralaxin in the Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial showed improved 6-month mortality but not the readmission rate or the composite end point of cardiovascular death or readmission to the hospital for HF or renal failure. The results of RELAX-AHF are promising but require confirmation. Therapies that improve postdischarge HHF outcomes are those that affect HF with reduced ejection fraction pathophysiology, and using HHF as an opportunity to optimize care, are initiated in-hospital and continued after discharge (eg, angiotensin-converting-enzyme inhibitors or β -blockers).⁵²⁻⁵⁵ Drugs targeting dyspnea and hemodynamics are usually given intravenously at doses aiming to reverse pulmonary pressures rapidly. Such doses may not be needed for disease modification over long term and may lead to adverse effects (eg, angiotensin-converting-enzyme inhibitor was related to hypotension when given acutely intravenously for patients with acute myocardial infarction, whereas chronic oral use improves outcomes).⁵⁶

Approaches to Future Clinical Trials

If HHF mostly represents worsening chronic HF with no entirely distinct pathophysiologic targets beyond those operative in




Figure 2. Daily implantable hemodynamic monitor-derived pressures in patients with heart failure (HF). Trends in daily median implantable monitor-derived pressures are shown beginning 60 days before a hypervolemic HF-related event and continuing for 14 days after. Open blue circles represent low ejection fraction and closed red squares preserved ejection fraction patients with HF. Right ventricular systolic pressure (A) and diastolic pressure (B), and an estimate of pulmonary artery diastolic pressure (C) are shown. In both group of patients, an increase was found preceding the event in all 3 pressures, which returned to baseline after treatment. ePAD indicates estimated pulmonary artery diastolic pressure; and RV, right ventricle. Reprinted from Zile et al¹⁹ with permission of the publisher. © 2008, *Circulation*. 118:1433–1441.

chronic HF known, and that the highest risk for adverse events are after discharge among these patients, these facts then have important implications for trial design in HHF. Moving forward, based on the current pathophysiologic understanding and the past experiences with clinical trials, there are several possibilities for study design for patients with HHF (Figure 4).

In-Hospital Short-Term Infusions

This most commonly applied approach has failed with many drugs, raising the possibility that short-term infusions that do not affect the fundamental disease pathway but affects its secondary manifestation will not be successful. However, pulmonary pressures are associated with outcomes in HHF and it is also possible this approach might be effective with a given particular drug and whether this approach is matched with the most appropriate patient population. In addition, if a short-term infusion facilitated improved initiation, continuation, and titration of guideline-directed medical therapy after discharge, outcomes could be benefited. A short-term infusion of therapy, if efficacious for reducing mortality and readmission, has the distinct advantage of limiting duration of drug exposure and potentially side effects, as well as costs. Seralaxin has revived interest in this respect but is an early experience needing validation. It is humbling to note that multiple prior attempts with drugs tested on the basis of sound physiological

promise and positive preliminary data failed to improve clinical outcomes or were harmful with this approach.

In-Hospital Short-Term Infusions but Initiate Earlier

It is plausible that the strategy employing short-term infusion will improve outcomes if initiated earlier. It is argued that delay in initiating therapies leads to worsening ongoing myocardial and renal damage. Some observational studies have suggested that earlier initiation of intravenous diuretic and vasoactive medications is associated with better outcomes, whereas other studies have not.^{57,58} Secondary analysis of the RELAX-AHF data showed that seralaxin infusion was associated with improved natriuretic peptide, liver function, and cardiac troponin levels at 72 hours. Interestingly, RELAX-AHF trial started infusion at ≈ 12 hours after hospital presentation, which is earlier than other HHF trials. The ongoing Trial to Evaluate the Efficacy and Safety of Ularitide Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure (TRUE-AHF) is planning to enroll patients within 6 hours.⁵⁹ It has also argued that intravenous diuretics worsen neurohormonal activation, and earlier investigational therapy may prevent iatrogenic complications of loop diuretics. However, it has been demonstrated that adverse physiological changes in patients with HHF occur days to weeks before admission. It is not clear that a few hours

Table. Reported Pathophysiologic Abnormalities in Patients With Chronic and Hospitalized Heart Failure

Pathophysiology	Chronic Heart Failure	Heart Failure Hospitalization
Hemodynamics		
Central venous pressure, pulmonary artery pressure	↑	↔↑↑↑
Pulmonary capillary wedge pressure, systemic vascular resistance	↑	↔↑↑↑
Cardiac output	↔↓	↔↓
Neurohormonal activation		
Sympathetic nervous system	↔↑	↔↑↑↑
Renin-angiotensin-aldosterone system	↔↑	↔↑↑↑
Arginine vasopressin	↔↑	↔↑↑↑
Endothelin	↔↑	↔↑↑↑
Adrenomedullin	↔↑	↔↑↑↑
Myocyte damage		
Troponin	↔↑	↔↑↑
Inflammation		
C-Reactive protein, interleukin-6, tumor necrosis factor, ST-2	↔↑	↔↑↑↑
Oxidative stress		
Myeloperoxidases, uric acid	↔↑	↔↑↑
Extracellular matrix regulation		
Matrix metalloproteinase, tissue inhibitor of metalloproteinase, galactin-3	↔↑	↔↑↑↑
Natriuretic peptide		
B-type natriuretic peptide, N-terminal prohormone of B-type natriuretic peptide	↔↑	↔↑↑↑
Renal function and injury		
Blood urea nitrogen and creatinine	↔↑	↔↑↑
Cystatin C	↔↑	↔↑↑
Neutrophil gelatinase-associated lipocalin, kidney injury molecule-1	↔↑	↔↑↑
Endothelial function		
	↔↓	↔↓↓

difference in initiation of novel therapies in patients already receiving otherwise medications for congestion relieve can have a pronounced impact on long-term outcomes. However, it is conceivable that if an early infusion can avoid cardiorenal or other end-organ damage, or limit its extent, then this approach can be beneficial. The degree to which decompensated HF leads to permanent organ damage, however, is not clear.

Target the Immediate Postdischarge Phase

Because the postdischarge risk among patients with HHF seems to be primarily within the first few weeks to months after discharge, 1 option is to target this vulnerable phase when patients are at the highest risk. The use of subcutaneous natriuretic peptide in patients with HHF after discharge for 8 weeks has been showed to improve cardiac function and quality of life scores.⁶⁰ Another trial with this strategy that is currently enrolling patients is the Functional Impact of GLP-1 (glucagon-like peptide-1) for Heart Failure Treatment (FIGHT) trial testing 3 months of subcutaneous GLP-1




Figure 3. Changes in risk profile after hospitalization. Hazard ratios and 95% confidence intervals of all-cause mortality after discharge from hospital for first hospitalization for heart failure (HF) at various time intervals after discharge adjusted for other baseline predictors. Reprinted from Solomon et al⁴⁹ with permission of the publisher. © 2007, *Circulation*. 116:1482-1487.

agonist initiated at the time of discharge among patients with HHF. Targeting the vulnerable phase after discharge makes intuitive sense; however, the vulnerable phase hypothesis has not been proven. An alternate explanation to the observed highest risk in the immediate postdischarge phase that seems to decrease over time is that the highest risk patients die earlier after discharge leaving behind a population of patients with lower absolute risk translating into changes in observed risk over time. Giving long-term injections is challenging and even with oral drugs, limiting effective therapy to a short time assuming that the targeted abnormality is normalized, is unlikely. Indeed, some of these abnormalities may improve over time, but without fundamentally changing the HF state, they are unlikely to completely reverse, and limiting therapy rather than long-term continuation, waiting for another exacerbation to use them, is less appealing. However, if this approach allows patients to be bridged to achieve optimal initiation and titration of guideline-directed medical and device therapy as indicated over the ensuing months after discharge, this may be an attractive and ultimately successful approach.

Initiate Therapies During Hospitalization for Long-Term Use

Another approach is to consider HHF as a marker of high-risk patients with HF and using admission as an opportunity to initiate effective long-term therapies. Indeed, initiation of angiotensin-converting enzyme inhibitors or β -blockers during HHF has been associated with improved outcomes in patients with HF and reduced ejection fraction.⁵²⁻⁵⁵ Any pathway that is effectively targeted in patients with HHF is unlikely to be completely reversed in any short time frame to allow for safe discontinuation of therapy. This approach permits long-term exposure of effective therapies, possibly at lower doses that may be safer and still effective, without the intent of using higher intravenous doses to acutely reverse hemodynamic abnormalities. Although promising, 2 trials using this approach did not improve postdischarge outcomes, including the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST)⁶ and




Figure 4. Options for targeting therapy at various stages during hospitalization.

Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).⁶¹ Whether this failure to demonstrate efficacy was related to the drugs that were tested or the patient population chosen can be debated. However, both EVEREST and ASTRONAUT were successful in enrolling patients with sufficient event risk where the effect on primary outcomes could be readily determined, which is a significant additional benefit of this design.

In-Hospital Infusion Followed by Postdischarge Administration

Potentially one can combine several options listed above. For example, a novel therapy may be available in both intravenous infusion form for early in-hospital use but may be continued after discharge for short term or long term in the form of subcutaneous injections or an oral formulation. One example of such an approach potentially under current development is omecamtiv mecarbil, with which a phase II short-term intravenous use trial just completed enrollment, the Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF), whereas another trial with an oral formulation, the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF), is under way. If any particular drug does show benefit with this approach, it has the obvious significant benefit of bridging the acute early phase to more chronic use with an effective agent.

Conclusions

The HHF population is currently a significant health and healthcare burden to the society. Even if the hospitalization rates fall, with the growing elderly population and the increasing prevalence of HF, the actual numbers of HHF are projected to grow. There are no targeted therapies for these patients that

can reduce the risk of mortality or readmissions after discharge. Many trials have attempted to alter the outcomes of these patients with novel therapies, but the results have been disappointing. It is possible that this lack of success may partially be related to trial design and execution. In this respect, there are multiple options for testing the timing and duration for new drugs for patients with HHF, but all have their pros and cons. Clinical trials should consider these opportunities and challenges carefully, as besides the pharmacological properties of the drugs, these factors may well determine the fate of the intervention. These options should also be taken into the context of the clinical scenario and the patient substrate, (eg, there may be a differential benefit of earlier treatment if it is instituted before a possible cardiorenal injury, as opposed to once the injury has taken place). Future research leading to better understanding of HHF triggers, and pathophysiology may make the selection from the possible choices more obvious.

Sources of Funding

This work was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures

Dr Gheorghide has received funding from the following: Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd, CorThera, Cytokinetics, CytoPhex, Inc, DebioPharm S.A., Errekappa Terapeutici, GlaxoSmithKline, Ikarria, Intersection Medical, INC, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Pharmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America, Inc and Trevena Therapeutics; and has received significant (>\$10,000) support from Bayer Schering Pharma AG, DebioPharm

S.A., Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals, Sticars InterACT, and Takeda Pharmaceuticals North America, Inc.

References

- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics—2010 update: A report from the American heart association. *Circulation*. 2010;121:e46–e215.
- Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiane M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. *J Am Coll Cardiol*. 2007;50:768–777.
- Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J*. 2005;149:209–216.
- Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiane M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. *JAMA*. 2002;287:1541–1547.
- Gheorghiane M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA*. 2007;297:1332–1343.
- Konstam MA, Gheorghiane M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA*. 2007;297:1319–1331.
- McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *JAMA*. 2007;298:2009–2019.
- Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Pöder P, Kivikko M; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. *JAMA*. 2007;297:1883–1891.
- Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA*. 2005;293:1900–1905.
- Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. *Circulation*. 2005;111:1487–1491.
- Packer M. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. *Am Heart J*. 2000;139:S202–S206.
- Gheorghiane M, Pang PS, O'Connor CM, Prasad K, McMurray J, Teerlink JR, Fiuzat M, Sabbah H, Komajda M. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. *Am Heart J*. 2011;161:224–232.
- Gheorghiane M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. *Circulation*. 2005;112:3958–3968.
- Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. *Am J Med*. 2003;114:625–630.
- Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. *Circulation*. 2007;116:1549–1554.
- Yamokoski LM, Haas GJ, Gans B, Abraham WT. OptiVol fluid status monitoring with an implantable cardiac device: a heart failure management system. *Expert Rev Med Devices*. 2007;4:775–780.
- Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, Cowie MR. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. *Eur Heart J*. 2011;32:2266–2273.
- Vollmann D, Nägele H, Schauer P, Wiegand U, Butter C, Zanotto G, Quesada A, Guthmann A, Hill MR, Lamp B; European InSync Sentry Observational Study Investigators. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. *Eur Heart J*. 2007;28:1835–1840.
- Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. *Circulation*. 2008;118:1433–1441.
- Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton A, Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, Heywood JT, Frampton CM, Abraham WT; Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) Study Group. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. *Circulation*. 2010;121:1086–1095.
- Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation*. 2005;112:3738–3744.
- Tribouilloy C, Rusinaru D, Leborgne L, Mahjoub H, Szymanski C, Houpe D, Béguin M, Peltier M. In-hospital mortality and prognostic factors in patients admitted for new-onset heart failure with preserved or reduced ejection fraction: a prospective observational study. *Arch Cardiovasc Dis*. 2008;101:226–234.
- Verhaert D, Mullens W, Borowski A, Popović ZB, Curtin RJ, Thomas JD, Tang WH. Right ventricular response to intensive medical therapy in advanced decompensated heart failure. *Circ Heart Fail*. 2010;3:340–346.
- Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J*. 2006;27:2725–2736.
- Binayan C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA*. 2005;294:1625–1633.
- Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. *N Engl J Med*. 1999;341:577–585.
- Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. *Am J Cardiol*. 2003;91:245–248.
- Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. *J Am Coll Cardiol*. 2009;54:1747–1762.
- Potocki M, Breidhardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. *Crit Care*. 2009;13:R122.
- Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. *Circulation*. 2003;108:833–838.

31. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. *N Engl J Med*. 2008;358:2117–2126.
32. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). *J Am Coll Cardiol*. 1996;27:1201–1206.
33. Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. *Am Heart J*. 2006;151:845–850.
34. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. *Clin Cardiol*. 1999;22:811–813.
35. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. *J Am Coll Cardiol*. 2008;52:1458–1465.
36. Ungvári Z, Gupte SA, Recchia FA, Bátkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. *Curr Vasc Pharmacol*. 2005;3:221–229.
37. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. *J Am Coll Cardiol*. 2007;49:2364–2370.
38. Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. *Congest Heart Fail*. 2011;17:25–30.
39. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Antolinos MJ, Ruyter JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. *Eur J Heart Fail*. 2007;9:518–524.
40. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiuamont-Vin J, Li M, Hanriot D, Zannad F. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. *J Card Fail*. 2008;14:467–474.
41. Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Mizuno K. Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. *Int Heart J*. 2010;51:404–410.
42. Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, Wynne J; ADHERE Scientific Advisory Committee and Investigators. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. *Am J Cardiol*. 2008;101:231–237.
43. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghide M, Heywood JT, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). *Circulation*. 2010;122:585–596.
44. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. *JAMA*. 2003;290:2581–2587.
45. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005;293:572–580.
46. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghide M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. *Circ Heart Fail*. 2008;1:98–106.
47. Manzano-Fernandez S, Januzzi JL Jr, Boronat-García M, Bonaque-Gonzalez JC, Truong QA, Pastor-Perez FJ, Munoz-Esparza C, Pastor P, Albaladejo-Oton MD, Casas T, Valdes M, Pascual-Figal DA. Beta-trace protein and cystatin c as predictors of long-term outcomes in patients with acute heart failure. *J Am Coll Cardiol*. 2011;57:849–858.
48. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. *J Card Fail*. 2010;16:49–54.
49. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation*. 2007;116:1482–1487.
50. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J*. 2007;154:260–266.
51. Kaul P, McAlister FA, Ezekowitz JA, Grover VK, Quan H. Ethnic differences in 1-year mortality among patients hospitalised with heart failure. *Heart*. 2011;97:1048–1053.
52. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghide M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. *JAMA*. 2007;297:61–70.
53. Krantz MJ, Havranek EP, Haynes DK, Smith I, Bucher-Bartelson B, Long CS. Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study. *J Card Fail*. 2008;14:303–309.
54. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghide M; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. *J Am Coll Cardiol*. 2004;43:1534–1541.
55. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghide M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (optimize-hf). *Am Heart J*. 2007;153:82 e81–11.
56. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med*. 1992;327:678–684.
57. Peacock WF, Fonarow GC, Emerman CL, Mills RM, Wynne J. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in adhere. *Cardiology*. 2007;107:44–51.
58. Wong Y, Fonarow G, Mi X, Mills R, Peacock F, Curtis L, Qualls L, Klaskala W, Hernandez AF. Time to intravenous therapy and clinical outcomes in older patients presenting with acute decompensated heart failure: An analysis of the adhere registry emergency module. *J Am Coll Cardiol*. 2013;61:E622.
59. Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. *Am Heart J*. 2005;150:1239.
60. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. *J Am Coll Cardiol*. 2012;60:2305–2312.
61. Gheorghide M, Albaghdadi M, Zannad F, Fonarow GC, Böhm M, Gimpelewicz C, Botha J, Moores S, Lewis EF, Rattunde H, Maggioni A; ASTRONAUT Investigators and Study Coordinators. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). *Eur J Heart Fail*. 2011;13:100–106.

KEY WORDS: clinical trial ■ heart failure ■ hospitalization ■ prognosis

Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure

Catherine N. Marti, Gregg C. Fonarow, Mihai Gheorghiade and Javed Butler

Circ Heart Fail. 2013;6:1095-1101

doi: 10.1161/CIRCHEARTFAILURE.113.000518

Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circheartfailure.ahajournals.org/content/6/5/1095>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Heart Failure* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation: Heart Failure* is online at:
<http://circheartfailure.ahajournals.org/subscriptions/>